Advice
In the absence of a submission from the holder of the marketing authorisation
ibritumomab tiuxetan (Zevalin) is not recommended for use within NHSScotland as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- ibritumomab tiuxetan 1.6mg/ml (Zevalin)
- SMC ID:
- 499/08
- Indication:
- for the treatment of follicular lymphoma
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 August 2008